CervoMed Inc.
About CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.0M
- Net income
- -$27.0M
- Total assets
- $22.9M
- Market cap
- $27.2M
- Operating margin
- -706.2%
- Net margin
- -673.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.0M
- Operating expenses
- $32.3M
- Operating income
- -$28.3M
- Income tax
- $0
- Net income
- -$27.0M
- EPS (basic)
- $-2.98
Balance sheet
- Total assets
- $22.9M
- Current assets
- $22.9M
- Total liabilities
- $4.7M
- Current liabilities
- $4.7M
- Shareholders’ equity
- $18.2M
Cash flow
- Operating cash flow
- -$23.4M
- Investing cash flow
- $18.1M
- Financing cash flow
- $4.6M
- Net cash flow
- -$764.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $27.2M
- Shares outstanding
- 9.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 1996
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $27.0M in FY2025.
- Revenue declined 44% from FY2023 to FY2025.
- Trading 73% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CervoMed Inc..
Write a review
News about CervoMed Inc.
News & sentiment via Polygon.io
